KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Net Margin (2016 - 2025)

NovoCure's Net Margin history spans 12 years, with the latest figure at 14.05% for Q4 2025.

  • For Q4 2025, Net Margin rose 2683.0% year-over-year to 14.05%; the TTM value through Dec 2025 reached 20.79%, up 708.0%, while the annual FY2025 figure was 20.79%, 708.0% up from the prior year.
  • Net Margin for Q4 2025 was 14.05% at NovoCure, up from 22.29% in the prior quarter.
  • Across five years, Net Margin topped out at 3.06% in Q1 2021 and bottomed at 45.55% in Q2 2023.
  • The 5-year median for Net Margin is 22.17% (2025), against an average of 23.55%.
  • The largest annual shift saw Net Margin tumbled -4005bps in 2023 before it skyrocketed 2683bps in 2025.
  • A 5-year view of Net Margin shows it stood at 19.86% in 2021, then crashed by -46bps to 29.05% in 2022, then dropped by -21bps to 35.19% in 2023, then decreased by -16bps to 40.88% in 2024, then soared by 66bps to 14.05% in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Net Margin are 14.05% (Q4 2025), 22.29% (Q3 2025), and 25.28% (Q2 2025).